<div id="readability-page-1"><p>Cytek Biosciences, Inc. (<span>CTKB</span>) has disclosed a new risk, in the Capital Markets category.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>The analyst notes that Cytek Biosciences, Inc. faces heightened exposure to shifting tariffs and trade restrictions that could raise component costs and erode its pricing competitiveness globally. Any escalation in U.S.–China tensions, sanctions, or broader protectionist measures could disrupt key suppliers, dampen international demand, and materially pressure its margins and overall financial performance.</p> <p>The average CTKB <span>stock price target</span> is $6.25, implying 35.57% upside potential.</p> <p>To learn more about Cytek Biosciences, Inc.’s risk factors, <span>click here</span>.</p></div>

CTKB

SBIO

LABU

<p>Cytek Biosciences, Inc. (CTKB) is facing increased risks due to U.S.–China trade tensions and tariff pressures, which may raise component costs and impact pricing competitiveness. Escalating tensions could disrupt suppliers and reduce international demand, affecting margins and financial performance. The average stock price target for CTKB is $6.25, indicating a potential upside of 35.57%.</p>

Tip Ranks

Cytek Biosciences

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Cytek Biosciences Faces Rising Risk From U.S.–China Trade Tensions and Tariff Pressures